Send In The Senolytics

Elie Dolgin's recent article in Nature Biotechnology explains why the failure of the first senolytic drug to enter clinical trials is far from being a refutation of the senolytic hypothesis, and reviews the growing arsenal of other senolytics currently in development - including work by SRF's Dr. Amit Sharma and SRF-supported startup Oisín Biotechnologies.

Elie Dolgin’s recent article in Nature Biotechnology explains why the apparent failure of the first senolytic drug to enter clinical trials is far from being a refutation of the senolytic hypothesis, and reviews the growing arsenal of other senolytics currently in development – including work by SRF’s Dr. Amit Sharma and SRF-supported startup Oisín Biotechnologies.

We respect your privacy. You can unsubscribe at any time.

Use of this Web site constitutes acceptance of the Terms of Use and Privacy Policy.

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Functional

Performance

Analytics

Others

Send In The Senolytics

Recent Posts:

AmyloSENS Therapies for Alzheimer’s: The Marathon and the Decathlon

More Studies on Metformin and Survival

Sponsor a Student

Set My Heart Free: Two AmyloSENS Therapies Targeting Cardiac Amyloid in Clinical Trials

The Grand Opening of Our New Facilities

From Parachutes to Jetpacks: Clearing Brain Beta-Amyloid with Donanemab or Lecanemab Works, Though More Must be Done

Lights, Camera, Action on AI-Powered Drug Discovery

Announcing the Biomarkers of Aging Consortium

Action at the Governmental Level for Longevity

Scenes from the Lab

A Busy Spring in the Education Department

New Peer-Reviewed Paper from SENS Research Foundation: Iron Homeostasis as a Senolytic Target

About Us

Our Research

Education Opportunities

Get Involved

Receive our NewslEtter

We respect your privacy. You can unsubscribe at any time.

About Us

Our Research

Education Opportunities

Get Involved

Receive our NewslEtter

We respect your privacy. You can unsubscribe at any time.

Thank you for Subscribing to the SENS Research Foundation Newsletter.

You can also

or

You can